See more : Discover Financial Services (DFS) Income Statement Analysis – Financial Results
Complete financial analysis of CNBX Pharmaceuticals Inc. (CNBX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CNBX Pharmaceuticals Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- China National Building Material Company Limited (CBUMY) Income Statement Analysis – Financial Results
- Safe and Green Development Corporation (SGD) Income Statement Analysis – Financial Results
- DAEA TI Co., Ltd. (045390.KQ) Income Statement Analysis – Financial Results
- Riba Textiles Limited (RIBATEX.BO) Income Statement Analysis – Financial Results
- Agriculture & Natural Solutions Acquisition Corporation Warrant (ANSCW) Income Statement Analysis – Financial Results
CNBX Pharmaceuticals Inc. (CNBX)
About CNBX Pharmaceuticals Inc.
CNBX Pharmaceuticals Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of cannabinoid-based treatments and therapies for cancer. Its lead product candidate is RCC-33, an oral capsule containing a formulation of cannabinoids for the treatment of colorectal cancer. The company is also developing various drug candidates, including PLP-33 for the treatment of lateral spreading or sessile, and colorectal polyps during colonoscopy; BRST-33 to treat breast cancer; MLN-33 for the treatment of Melanoma; and PRST-33 to treat prostate cancer. In addition, it develops Cannabics SR, a lipid-based capsule containing a standardized formulation of cannabinoids for the treatment of cancer anorexia-cachexia syndrome; and Cannabics CDx, an ex-vivo drug sensitivity test. The company was formerly known as Cannabics Pharmaceuticals Inc. and changed its name to CNBX Pharmaceuticals Inc. in March 2022. CNBX Pharmaceuticals Inc. was incorporated in 2004 and is based in Bethesda, Maryland. CNBX Pharmaceuticals Inc. is a subsidiary of Cannabics Inc.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 130.07K | 410.17K | 29.96K | 0.00 | 7.16K | 9.84K | 9.60K | 5.68K | 112.50K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 198.53K | 220.93K | 0.00 | 0.00 | 1.00 | 7.02K | 0.00 | 0.00 | 0.00 | 58.11K | 1.65K | 144.41K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 130.07K | 410.17K | -168.57K | -220.93K | 7.16K | 9.84K | 9.60K | -1.34K | 112.50K | 0.00 | 0.00 | -58.11K | -1.65K | -144.41K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 100.00% | 100.00% | -562.68% | 0.00% | 100.00% | 100.00% | 99.99% | -23.49% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 194.79K | 431.57K | 1.18M | 1.77M | 1.68M | 1.54M | 1.00M | 246.94K | 177.61K | 139.44K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 105.23K | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 518.43K | 894.00K | 1.75M | 808.40K | 1.31M | 1.48M | 2.39M | 1.33M | 214.61K | 327.25K | 210.65K | 57.93K | 19.89K | 21.32K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 15.98K | 15.98K | 20.25K | 60.00K | 288.16K | 422.02K | 287.46K | 960.00 | 62.72K | 0.00 | 0.00 | 495.00 | 2.11K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 518.43K | 909.98K | 1.77M | 828.64K | 1.37M | 1.77M | 2.81M | 1.61M | 215.57K | 389.96K | 210.65K | 57.93K | 20.39K | 23.43K | 27.43K | 9.69K | 12.46K | 21.27K | 19.19K | 1.74K |
| Other Expenses | -1.00 | 0.00 | -722.24K | -706.86K | -4.36M | 19.62K | -4.00 | 2.00 | -3.00 | 7.10K | 4.51K | 0.00 | 20.39K | 125.66K | 27.43K | 4.92K | 13.56K | 23.20K | -20.02K | 1.80K |
| Operating Expenses | 713.21K | 1.34M | 2.95M | 2.60M | 3.05M | 3.31M | 3.82M | 1.86M | 393.18K | 536.50K | 215.16K | 57.93K | 20.39K | 125.66K | 27.43K | 114.92K | 13.56K | 23.20K | -20.02K | 1.80K |
| Cost & Expenses | 713.21K | 1.34M | 2.95M | 2.60M | 3.05M | 3.31M | 3.82M | 1.86M | 393.18K | 536.50K | 215.16K | 57.93K | 20.39K | 125.66K | 27.43K | 114.92K | 13.56K | 23.20K | -20.02K | 1.80K |
| Interest Income | 0.00 | 0.00 | 1.27K | 2.39K | 8.13K | 4.36M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 19.61K | 1.17K | 1.27K | 2.39K | 8.13K | 18.35K | 852.00 | 4.37K | 27.18K | 3.03K | 971.00 | 179.00 | 13.00 | 10.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 72.32K | 162.06K | 198.53K | 220.93K | 215.16K | 188.93K | 88.44K | 7.02K | 1.58K | 1.30K | 86.00 | 179.00 | -37.49K | -214.22K | 167.48K | 0.00 | 1.08K | 1.08K | 0.00 | 0.00 |
| EBITDA | -603.27K | -3.55M | -3.52M | -3.15M | -7.24M | 1.34M | -3.72M | -1.92M | -278.42K | -540.09K | -218.09K | -56.22K | -21.55K | -165.73K | 56.31K | -114.92K | 1.41K | -21.27K | 20.02K | -1.80K |
| EBITDA Ratio | -463.79% | -864.77% | -11,608.52% | 0.00% | -101,317.54% | -31,444.24% | -39,083.42% | -32,492.59% | -248.09% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -583.14K | -931.38K | -2.95M | -2.60M | -3.04M | -3.30M | -3.81M | -1.85M | -280.68K | -539.53K | -216.13K | -58.11K | -1.65K | 144.41K | -111.17K | -114.92K | -27.46K | -23.20K | 20.02K | -1.80K |
| Operating Income Ratio | -448.31% | -227.07% | -9,860.37% | 0.00% | -42,524.12% | -33,563.01% | -39,670.12% | -32,616.08% | -249.49% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -112.06K | -2.78M | -769.28K | -594.27K | -4.42M | 4.44M | 32.11K | -79.94K | -26.50K | -1.86K | -3.01K | 1.53K | 36.99K | 55.73K | 1.17K | 4.92K | -16.44K | 3.20K | -40.02K | 0.00 |
| Income Before Tax | -695.20K | -3.71M | -3.72M | -3.19M | -7.47M | 1.13M | -3.78M | -1.93M | -307.18K | -541.39K | -219.14K | -56.40K | 17.10K | -110.00K | -110.00K | -110.00K | -30.00K | -20.00K | -20.00K | 0.00 |
| Income Before Tax Ratio | -534.46% | -904.57% | -12,428.23% | 0.00% | -104,337.88% | 11,510.41% | -39,335.66% | -34,022.54% | -273.05% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 0.00 | 45.77K | -704.47K | -4.35M | 37.97K | 32.96K | 4.37K | 27.18K | 3.03K | 50.86K | 0.00 | 18.75K | 195.87K | -79.93K | 4.92K | 13.90K | 3.20K | 21.00 | 1.80K |
| Net Income | -695.20K | -3.71M | -3.77M | -2.49M | -3.11M | 1.13M | -3.78M | -1.93M | -307.18K | -541.39K | -270.01K | -56.40K | -1.65K | -107.31K | -114.98K | -114.92K | -27.46K | -23.20K | -20.02K | -1.80K |
| Net Income Ratio | -534.46% | -904.57% | -12,581.02% | 0.00% | -43,490.25% | 11,510.41% | -39,335.66% | -34,022.54% | -273.05% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.02 | -0.42 | -3.08 | -2.16 | -2.78 | 1.03 | -3.76 | -2.10 | -0.36 | -0.65 | -0.32 | -4.98 | -0.15 | -9.47 | -10.14 | -10.14 | -2.42 | -2.05 | -2.40 | -0.86 |
| EPS Diluted | -0.02 | -0.42 | -3.08 | -2.16 | -2.78 | 1.03 | -3.76 | -2.10 | -0.36 | -0.65 | -0.32 | -4.98 | -0.15 | -9.47 | -10.14 | -10.14 | -2.42 | -2.05 | -2.40 | -0.86 |
| Weighted Avg Shares Out | 30.25M | 8.82M | 1.22M | 1.15M | 1.12M | 1.10M | 1.00M | 919.80K | 860.45K | 839.19K | 835.38K | 11.34K | 11.34K | 11.34K | 11.34K | 11.34K | 11.34K | 11.34K | 8.33K | 2.09K |
| Weighted Avg Shares Out (Dil) | 30.25M | 8.82M | 1.22M | 1.15M | 1.12M | 1.10M | 1.00M | 919.80K | 860.45K | 839.19K | 835.38K | 11.34K | 11.34K | 11.34K | 11.34K | 11.34K | 11.34K | 11.34K | 8.33K | 2.09K |
CEO of Cannabics Pharmaceuticals, Eyal Barad, to present at Edison Open Forum: Cannabinoids 2021
TEL AVIV, Israel and BETHESDA, Md., Oct. 19, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTC: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that Company CEO, Eyal Barad, will present at the upcoming Edison Open Forum: Cannabinoids 2021,...
Cannabics Pharmaceuticals Announces Two New Provisional Patents: Compositions and Methods For Treating Cancer
Cannabics Pharmaceuticals Inc. (OTC:CNBX), a global leader in the development of cancer-related cannabinoid-based medicine, announced on Monday that it has filed two new provisional patent applications on Compositions and Methods for treating cancer, including colorectal cancer and early intervention therapy for...
Cannabics Pharmaceuticals Files 2 Provisional Patents On Compositions and Methods for Treating Cancer
TEL AVIV, Israel and BETHESDA, Md., Oct. 18, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTC: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that it has filed 2 new Provisional Patent applications on Compositions and Methods for treating...
Cannabics Announces New Corporate Logo, New Website and New Company Presentation
TEL AVIV, Israel and BETHESDA, Md., Sept. 30, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine and a pioneer in the development of psychedelic inspired medicine, announced today that it has updated...
Gabriel Yariv, Executive Director of Cannabics Pharmaceuticals and Dr. David Sans will participate at the ICDP Summit in Boston
TEL AVIV, Israel and BETHESDA, Md., Sept. 22, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that the Company will present at the 4th Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston.
Cannabics Pharmaceuticals hires Healthcare Investment Banker Dr. David Sans in New York to expand CNBX in Mental Health Diseases
TEL AVIV, Israel and BETHESDA, Maryland, Sept. 21, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today the hire of Dr. David Sans FAARM, PhD, MBA in New York to...
Neuropsychiatry Expert Dr. Ilya Reznik (MD) Joins Cannabics as Head of Psychedelic Inspired Medicine
TEL AVIV, Israel and BETHESDA, Md., Sept. 13, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine and a pioneer in the development of psychedelic inspired medicine, announced today that Dr. Ilya Reznik...
World-Renowned Melanoma Expert Joins Cannabics Pharmaceuticals' Board of Advisors
TEL AVIV, Israel and BETHESDA, Maryland, Aug. 4, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that Prof. Caroline Robert (MD.
Cannabics Pharmaceuticals Appoints a Second Independent Board Member
TEL AVIV, Israel and BETHESDA, Maryland, July 20, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that it has appointed Dr. Gil Feiler to its Board of Directors as an...
Cannabics Pharmaceuticals Announces Appointment of New Independent Board Member
TEL AVIV, Israel and BETHESDA, Md., July 7, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that it has appointed Dr. Inbar Maymon-Pomeranchik to its Board of Directors as an...
Source: https://incomestatements.info
Category: Stock Reports